A meta-analysis comparing responses of Asian versus non-Asian cancer patients to PD-1 and PD-L1 inhibitor-based therapy

References

• Hegde PS, Karanikas V, Evers S. The where, the when, and the how of immune monitoring for cancer immunotherapies in the era of checkpoint inhibition. Clin Cancer Res. 2016;22(8):1865–8. doi:10.1158/1078-0432.CCR-15-1507.
   PubMed Web of Science ®Google Scholar
• Sun C, Mezzadra R, Schumacher TN. Regulation and function of the PD-L1 checkpoint. Immunity. 2018;48(3):434–452. doi:10.1016/j.immuni.2018.03.014.
   PubMed Web of Science ®Google Scholar
• Kyi C, Postow MA. Immune checkpoint inhibitor combinations in solid tumors: opportunities and challenges. Immunotherapy. 2016;8(7):821–837. doi:10.2217/imt-2016-0002.
   PubMed Web of Science ®Google Scholar
• Ramamoorthy A, Pacanowski MA, Bull J, Zhang L. Racial/ethnic differences in drug disposition and response: review of recently approved drugs. Clin Pharmacol Ther. 2015;97(3):263–273. doi:10.1002/cpt.61.
   PubMed Web of Science ®Google Scholar
• Ozdemir BC, Dotto GP. Racial differences in cancer susceptibility and survival: more than the color of the skin? Trends Cancer. 2017;3(3):181–197. doi:10.1016/j.trecan.2017.02.002.
   PubMed Web of Science ®Google Scholar
• Soo RA, Loh M, Mok TS, Ou SH, Cho BC, Yeo WL, et al. Ethnic differences in survival outcome in patients with advanced stage non-small cell lung cancer: results of a meta-analysis of randomized controlled trials. J Thorac Oncol. 2011;6(6):1030–1038. doi:10.1097/JTO.0b013e3182199c03.
   PubMed Web of Science ®Google Scholar
• Cheng Y, Zhang L, Hu J, Wang D, Hu C, Zhou J, et al. KEYNOTE-407 China extension study: pembrolizumab (pembro) plus chemotherapy in Chinese patients with metastatic squamous NSCLC. Ann Oncol. 2019;30(suppl_9):ix183–ix202. doi:10.1093/annonc/mdz446.
   Google Scholar
• Peng L, Wu YL. Immunotherapy in the Asiatic population: any differences from Caucasian population? J Thorac Dis. 2018;10(Suppl 13):S1482–S93. doi:10.21037/jtd.2018.05.106.
   PubMedGoogle Scholar
• Altman DG, Bland JM. Interaction revisited: the difference between two estimates. BMJ. 2003;326(7382):219. doi:10.1136/bmj.326.7382.219.
   PubMed Web of Science ®Google Scholar
• Conforti F, Pala L, Bagnardi V, Viale G, De Pas T, Pagan E, et al. Sex-based heterogeneity in response to lung cancer immunotherapy: a systematic review and meta-analysis. J Natl Cancer Inst. 2019;111(8):772–781. doi:10.1093/jnci/djz094.
   PubMedGoogle Scholar
• Zintzaras E, Ioannidis JP. Heterogeneity testing in meta-analysis of genome searches. Genet Epidemiol. 2005;28(2):123–137. doi:10.1002/gepi.20048.
   PubMed Web of Science ®Google Scholar
• Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis. 1985;27(5):335–371. doi:10.1016/S0033-0620(85)80003-7.
   PubMed Web of Science ®Google Scholar
• Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50(4):1088–1101. doi:10.2307/2533446.
   PubMed Web of Science ®Google Scholar
• Ferris RL, Blumenschein G Jr., Fayette J, Guigay J, Colevas AD, Licitra L, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375(19):1856–1867. doi:10.1056/NEJMoa1602252.
   PubMed Web of Science ®Google Scholar
• Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fulop A, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(19):1823–1833. doi:10.1056/NEJMoa1606774.
   PubMed Web of Science ®Google Scholar
• Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med. 2017;377(20):1919–1929. doi:10.1056/NEJMoa1709937.
   PubMed Web of Science ®Google Scholar
• Hellmann MD, Ciuleanu TE, Pluzanski A, Lee JS, Otterson GA, Audigier-Valette C, et al. Nivolumab plus Ipilimumab in lung cancer with a high tumor mutational burden. N Engl J Med. 2018;378(22):2093–2104. doi:10.1056/NEJMoa1801946.
   PubMed Web of Science ®Google Scholar
• Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018;379(22):2108–2121. doi:10.1056/NEJMoa1809615.
   PubMed Web of Science ®Google Scholar
• Papadimitrakopoulou V, Cobo M, Bordoni R, Dubray-Longeras P, Szalai Z, Ursol G, et al. IMpower132: PFS and safety results with 1L Atezolizumab + Carboplatin/Cisplatin + Pemetrexed in Stage IV non-squamous NSCLC. J Thoracic Oncol. 2018;13(10):S332–S3. doi:10.1016/j.jtho.2018.08.262.
   Web of Science ®Google Scholar
• Bang YJ, Ruiz EY, Van Cutsem E, Lee KW, Wyrwicz L, Schenker M, et al. Phase III, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300. Ann Oncol. 2018;29(10):2052–2060. doi:10.1093/annonc/mdy264.
   PubMed Web of Science ®Google Scholar
• Shitara K, Ozguroglu M, Bang YJ, Di Bartolomeo M, Mandala M, Ryu MH, et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet. 2018;392(10142):123–133. doi:10.1016/S0140-6736(18)31257-1.
   PubMed Web of Science ®Google Scholar
• Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gumus M, Mazieres J, et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med. 2018;379(21):2040–2051. doi:10.1056/NEJMoa1810865.
   PubMed Web of Science ®Google Scholar
• Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019;394(10212):1929–1939. doi:10.1016/S0140-6736(19)32222-6.
   PubMed Web of Science ®Google Scholar
• Reck M, Vicente D, Ciuleanu T, Gettinger S, Peters S, Horn L, et al. Efficacy and safety of nivolumab (nivo) monotherapy versus chemotherapy (chemo) in recurrent small cell lung cancer (SCLC): results from checkMate 331. Ann Oncol. 2018;29(suppl_10):x39–x43. doi:10.1093/annonc/mdy511.
   Google Scholar
• Yau T, Park JW, Finn RS, Cheng A, Mathurin P, Edeline J, et al. CheckMate 459: a randomized, multi-center phase 3 study of Nivolumab (NIVO) vs Sorafenib (SOR) as First-Line (1L) treatment in patients (pts) with advanced Hepatocellular Carcinoma (aHCC). Ann Oncol. 2019;30(suppl_5):v874–v875. doi:10.1093/annonc/mdz394.029.
   Google Scholar
• Spigel D, Marinis F, Giaccone G, Reinmuth N, Vergnenegre A, Barrios CH, et al. IMpower110: interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo) vs platinum-based chemotherapy (chemo) as first-line (1L) treatment (tx) in PD-L1–selected NSCLC. Ann Oncol. 2019;30(suppl_5):v851–v934. doi:10.1093/annonc/mdz394.
   Google Scholar
• Jotte R, Cappuzzo F, Vynnychenko I, Stroyakovskiy D, Abreu DR, Hussein M, et al. IMpower131: final OS results of Carboplatin + Nab-Paclitaxel ± Atezolizumab in advanced squamous NSCLC. J Thoracic Oncol. 2019;14(10):S243–S4. doi:10.1016/j.jtho.2019.08.484.
   Web of Science ®Google Scholar
• Mok TSK, Wu Y, Kudaba I, Kowalski DM, Cho BC, Turna HZ, et al. Final analysis of the phase III KEYNOTE-042 study: pembrolizumab (Pembro) versus platinum-based chemotherapy (Chemo) as first-line therapy for patients (Pts) with PD-L1–positive locally advanced/metastatic NSCLC. Ann Oncol. 2019;30(Supplement_2):ii38–ii68. doi:10.1093/annonc/mdz063.
   Google Scholar
• Tabernero J, Eric Van Cutsem Y-JB, Fuchs CS, Wyrwicz L, Lee KW, Kudaba I, et al. Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: the phase III KEYNOTE-062 study. J Clin Oncol. 2019;37(18_suppl):LBA4007–LBA. doi:10.1200/JCO.2019.37.18_suppl.LBA4007.
   Web of Science ®Google Scholar
• Kojima T, Muro K, Francois E, Hsu C-H, Moriwaki T, Kim S-B, et al. Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: phase III KEYNOTE-181 study. J Clin Oncol. 2019;37(4_suppl):2. doi:10.1200/JCO.2019.37.4_suppl.2.
   Web of Science ®Google Scholar
• Moehler MH, Dvorkin M, Ozguroglu M, Ryu M-H, Muntean AS, Lonardi S, et al. Results of the JAVELIN Gastric 100 phase 3 trial: avelumab maintenance following first-line (1L) chemotherapy (CTx) vs continuation of CTx for HER2− advanced gastric or gastroesophageal junction cancer (GC/GEJC). J Clin Oncol. 2020;38(4_suppl):278. doi:10.1200/JCO.2020.38.4_suppl.278.
   Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097. doi:10.1371/journal.pmed.1000097.
   PubMed Web of Science ®Google Scholar
• Nazha B, Mishra M, Pentz R, Owonikoko TK. Enrollment of racial minorities in clinical trials: old problem assumes new urgency in the age of immunotherapy. Am Soc Clin Oncol Educ Book. 2019;39(39):3–10. doi:10.1200/EDBK_100021.
   PubMedGoogle Scholar
• Varlotto JM, Voland R, McKie K, Flickinger JC, DeCamp MM, Maddox D, et al. Population-based differences in the outcome and presentation of lung cancer patients based upon racial, histologic, and economic factors in all lung patients and those with metastatic disease. Cancer Med. 2018;7(4):1211–1220. doi:10.1002/cam4.1430.
   PubMed Web of Science ®Google Scholar
• Liu X, Fiocco M, Swen JJ, Guchelaar HJ. Assessment of ethnic differences in sunitinib outcome between Caucasian and Asian patients with metastatic renal cell carcinoma: a meta-analysis. Acta Oncol. 2017;56(4):582–589. doi:10.1080/0284186X.2016.1265666.
   PubMed Web of Science ®Google Scholar
• Chang E, Gong Y, Vallejo JJ, Liu Q, Mathieu LN, Booth B,et al. FDA analysis of outcomes in Asian patients (pts) with metastatic non-small cell lung cancer (mNSCLC) receiving immune checkpoint inhibitors (ICI). J Clin Oncol. 2019;37(15_suppl):e20690–e. doi:10.1200/JCO.2019.37.15_suppl.e20690.
   Google Scholar
• Juergens RA, Mariano C, Jolivet J, Finn N, Rothenstein J, Reaume MN, et al. Real-world benefit of nivolumab in a Canadian non-small-cell lung cancer cohort. Curr Oncol. 2018;25(6):384–392. doi:10.3747/co.25.4287.
   PubMed Web of Science ®Google Scholar
• Garassino MC, Gelibter AJ, Grossi F, Chiari R, Soto Parra H, Cascinu S, et al. Italian Nivolumab expanded access program in nonsquamous non-small cell lung cancer patients: results in never-smokers and EGFR-mutant patients. J Thorac Oncol. 2018;13(8):1146–1155. doi:10.1016/j.jtho.2018.04.025.
   PubMed Web of Science ®Google Scholar
• Song P, Zhang J, Shang C, Zhang L. Real-world evidenceand clinical observations of the treatment of advanced non-small cell lung cancer with PD-1/PD-L1 inhibitors. Sci Rep. 2019;9(1):4278. doi:10.1038/s41598-019-40748-7.
   PubMedGoogle Scholar
• Qian J, Nie W, Lu J, Zhang L, Zhang Y, Zhang B, et al. Racial differences in characteristics and prognoses between Asian and white patients with nonsmall cell lung cancer receiving atezolizumab: an ancillary analysis of the POPLAR and OAK studies. Int J Cancer. 2020;146(11):3124–3133. doi:10.1002/ijc.32717.
   Web of Science ®Google Scholar
• Skoulidis F, Goldberg ME, Greenawalt DM, Hellmann MD, Awad MM, Gainor JF, et al. STK11/LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma. Cancer Discov. 2018;8(7):822–835. doi:10.1158/2159-8290.CD-18-0099.
   PubMed Web of Science ®Google Scholar
• Schabath MB, Welsh EA, Fulp WJ, Chen L, Teer JK, Thompson ZJ, et al. Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma. Oncogene. 2016;35(24):3209–3216. doi:10.1038/onc.2015.375.
   PubMed Web of Science ®Google Scholar
• Feng Y, Wang X, Bajaj G, Agrawal S, Bello A, Lestini B, et al. Nivolumab exposure-response analyses of efficacy and safety in previously treated squamous or nonsquamous non-small cell lung cancer. Clin Cancer Res. 2017;23(18):5394–5405. doi:10.1158/1078-0432.CCR-16-2842.
   PubMed Web of Science ®Google Scholar
• Bajaj G, Wang X, Agrawal S, Gupta M, Roy A, Feng Y. Model-based population pharmacokinetic analysis of nivolumab in patients with solid tumors. CPT Pharmacometrics Syst Pharmacol. 2017;6(1):58–66. doi:10.1002/psp4.12143.
   PubMedGoogle Scholar
• Desnoyer A, Broutin S, Delahousse J, Maritaz C, Blondel L, Mir O, et al. Pharmacokinetic/pharmacodynamic relationship of therapeutic monoclonal antibodies used in oncology: part 2, immune checkpoint inhibitor antibodies. Eur J Cancer. 2020;128:119–128. doi:10.1016/j.ejca.2020.01.003.
   PubMed Web of Science ®Google Scholar